A carregar...
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipati...
Na minha lista:
| Publicado no: | Am J Gastroenterol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8183489/ https://ncbi.nlm.nih.gov/pubmed/33337659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/ajg.0000000000001056 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|